GAPT's mission is to ensure that a full-range of mental health treatment options are available in Georgia. We will closely monitor research and policy regarding psychedelics. We will work with other leading Georgia-based institutions in removing barriers to effective, scientifically-supported psychedelic interventions, and we will assist in establishing a certification process that ensures compliance.

• Safety

• Research

• Honesty

• Innovation

• Patient Rights

As noted before, our group is especially interested in the use of Ketamine, psilocybin, and MDMA. Because these interventions are in various stages regarding accessibility, for the purposes of Georgia, the GAPT Board has identified making psilocybin easily accessible to appropriate patients as our primary focal point.

• Years 1-2:

  • Raise public awareness about psychedelic therapies.

  • Support clinical trials and to gather data on the safety and efficacy of psilocybin.

  • Promote scientific exploration and collaboration through study committees.

• Years 3-4:

  • Advocate for legislative changes to allow psilocybin therapy in Georgia.

  • Develop a certification process for clinics to administer psilocybin therapy.

• Year 5:

  • Assist in certified clinics staying in compliance to provide psilocybin therapy under strict safety standards.

  • Implement ongoing monitoring to ensure patient well-being and effective treatment.